TY - JOUR
T1 - Standards of care for hypoparathyroidism in adults
T2 - A Canadian and international consensus
AU - Khan, Aliya A.
AU - Koch, Christian A.
AU - Van Uum, Stan
AU - Baillargeon, Jean Patrice
AU - Bollerslev, Jens
AU - Brandi, Maria Luisa
AU - Marcocci, Claudio
AU - Rejnmark, Lars
AU - Rizzoli, Rene
AU - Shrayyef, M. Zakarea
AU - Thakker, Rajesh
AU - Yildiz, Bulent O.
AU - Clarke, Bart
N1 - Funding Information:
A K: Research funds from Shire; C K: Novartis Pharma, Advisory Board Consultant, Shire Pharmaceuticals, Principal Investigator, A European Post-Authorisation Observational Study (Registry) of Patients With Chronic Adrenal 阀nsufficiency (A 阀), Springer Publisher, Royalty Honoraria (Book, Journals), Elsevier Publisher, Royalty Honorarium (Journal); S V U: Relationships with for-profit and not-for-profit interests: Grants/Research support: Novartis, Sanofi, Speakers Bureau/Honoraria: Abbott, Acerus pharmaceuticals, Novartis, 阀psen, Sanofi, Consulting Fees: Pfizer; J-P B: No conflict of interest to declare; J B: No disclosures; M L B: Received honoraria from Amgen, Bruno Farmaceutici, Kyowa Kirin; Academic grants and/or speaker: Abiogen, Alexion, Amgen, Bruno Farmaceutici, Eli Lilly, Kyowa Kirin, MSD, NPS, Servier, Shire, SPA; Consultant: Alexion, Bruno Farmaceutici, Kyowa Kirin, Servier, Shirel; C M: Consultant and speaker for Abiogen-Pharma and SHIRE, Research grant from SHIRE; L R: Speakers fee: Shire, Alexion, Eli Lilly, Amgen, Takeda Pharmaceuticals; Consultancy: Shire, Alexion and Kyowa Kirin; R R: Advisory board or speaker for Radius Health, Sandoz, E 贀ryx and Theramex; M Z S: Grants/Research Support: Eli Lilly, Valeant, Novo Nordisk Speakers Bureau/Honoraria/Consulting Fees: Novo Nordisk, Amgen, Merck; B Y: Nothing to disclose; R T: Research income from: Medical Research Council programme grant, Wellcome Trust Investigator Award, NIHR Senior Investigator, NIHR Translational Research Collaboration, NIHR Oxford Grant – BRC funding, Wellcome Trust clinical training fellowships, EU ITN Marie Curie grant, Glaxo-SmithKline research grant, Kidney Research UK (KRUK) project grant, Novartis Research Grant, NPS Pharmaceuticals (USA), Marshall Smith Syndrome Research Fund. Chairman of Astra-Zeneca Stratified Medicine Panel, Honoraria/lecture and consultancy fees from Novartis, Lilly, AstraZeneca and 阀psen; B C: Research grant support and consultant for Shire, Inc., Data monitoring board member for Amgen, Inc., Data monitoring board member for GSK.
Funding Information:
Canadian Endocrine Update, McMaster University and Western University for the completion of the literature review - 2018.
Publisher Copyright:
© 2019 The authors Published by Bioscientifica Ltd.
PY - 2019/3
Y1 - 2019/3
N2 - Purpose: To provide practice recommendations for the diagnosis and management of hypoparathyroidism in adults. Methods: Key questions pertaining to the diagnosis and management of hypoparathyroidism were addressed following a literature review. We searched PubMed, MEDLINE, EMBASE and Cochrane databases from January 2000 to March 2018 using keywords 'hypoparathyroidism, diagnosis, treatment, calcium, PTH, calcidiol, calcitriol, hydrochlorothiazide and pregnancy'. Only English language papers involving humans were included. We excluded letters, reviews and editorials. The quality of evidence was evaluated based on the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. These standards of care for hypoparathyroidism have been endorsed by the Canadian Society of Endocrinology and Metabolism. Results: Hypoparathyroidism is a rare disease characterized by hypocalcemia, hyperphosphatemia and a low or inappropriately normal serum parathyroid hormone level (PTH). The majority of cases are post-surgical (75%) with nonsurgical causes accounting for the remaining 25% of cases. A careful review is required to determine the etiology of the hypoparathyroidism in individuals with nonsurgical disea se. Hypoparathyroidism is associated with significant morbidity and poor quality of life. Treatment requires close monitoring as well as patient education. Conventional therapy with calcium supplements and active vitamin D analogs i s effective in improving serum calcium as well as in controlling the symptoms of hypocalcemia. PTH replacement is of value in lowering the doses of calcium and active vitamin D analogs required and may be of value in lowering long-term complications of hypoparathyroidism. This manuscript addresses acute and chronic management of hypoparathyroidism in adults. Main conclusions: Hypoparathyroidism requires careful evaluation and pharmacologic intervention in order to improve serum calcium and control the symptoms of hypocalcemia. Frequen t laboratory monitoring of the biochemical profile and patient education is essential to achieving optimal control of serum calcium.
AB - Purpose: To provide practice recommendations for the diagnosis and management of hypoparathyroidism in adults. Methods: Key questions pertaining to the diagnosis and management of hypoparathyroidism were addressed following a literature review. We searched PubMed, MEDLINE, EMBASE and Cochrane databases from January 2000 to March 2018 using keywords 'hypoparathyroidism, diagnosis, treatment, calcium, PTH, calcidiol, calcitriol, hydrochlorothiazide and pregnancy'. Only English language papers involving humans were included. We excluded letters, reviews and editorials. The quality of evidence was evaluated based on the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. These standards of care for hypoparathyroidism have been endorsed by the Canadian Society of Endocrinology and Metabolism. Results: Hypoparathyroidism is a rare disease characterized by hypocalcemia, hyperphosphatemia and a low or inappropriately normal serum parathyroid hormone level (PTH). The majority of cases are post-surgical (75%) with nonsurgical causes accounting for the remaining 25% of cases. A careful review is required to determine the etiology of the hypoparathyroidism in individuals with nonsurgical disea se. Hypoparathyroidism is associated with significant morbidity and poor quality of life. Treatment requires close monitoring as well as patient education. Conventional therapy with calcium supplements and active vitamin D analogs i s effective in improving serum calcium as well as in controlling the symptoms of hypocalcemia. PTH replacement is of value in lowering the doses of calcium and active vitamin D analogs required and may be of value in lowering long-term complications of hypoparathyroidism. This manuscript addresses acute and chronic management of hypoparathyroidism in adults. Main conclusions: Hypoparathyroidism requires careful evaluation and pharmacologic intervention in order to improve serum calcium and control the symptoms of hypocalcemia. Frequen t laboratory monitoring of the biochemical profile and patient education is essential to achieving optimal control of serum calcium.
UR - http://www.scopus.com/inward/record.url?scp=85061036087&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85061036087&partnerID=8YFLogxK
U2 - 10.1530/EJE-18-0609
DO - 10.1530/EJE-18-0609
M3 - Review article
C2 - 30540559
AN - SCOPUS:85061036087
SN - 0804-4643
VL - 180
SP - P1-P22
JO - European Journal of Endocrinology
JF - European Journal of Endocrinology
IS - 3
ER -